Clinical trial NCT05162027 - References

Temporomandibular Disorders — Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)

Citation(s)

•   Akerman S, Romero-Reyes M
  Preclinical studies investigating the neural mechanisms involved in the co-morbidity of migraine and temporomandibular disorders: the role of CGRP. Br J Pharmacol. 2020 Dec;177(24):5555-5568. doi: 10.1111/bph.15263. Epub 2020 Oct 21.
•   Ashina H, Iljazi A, Al-Khazali HM, Eigenbrodt AK, Larsen EL, Andersen AM, Hansen KJ, Brauner KB, Morch-Jessen T, Chaudhry B, Antic S, Christensen CE, Ashina M, Amin FM, Schytz HW
  Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study. J Headache Pain. 2020 Jun 3;21(1):62. doi: 10.1186/s10194-020-01136-z.
•   Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, Cheng S, Zhang F, Lenz R, Klatt J, Mikol DD
  Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018 Sep;38(10):1611-1621. doi: 10.1177/0333102418788347. Epub 2018 Jul 8.
•   Cady RJ, Glenn JR, Smith KM, Durham PL
  Calcitonin gene-related peptide promotes cellular changes in trigeminal neurons and glia implicated in peripheral and central sensitization. Mol Pain. 2011 Dec 6;7:94. doi: 10.1186/1744-8069-7-94.
•   Chen H, Slade G, Lim PF, Miller V, Maixner W, Diatchenko L
  Relationship between temporomandibular disorders, widespread palpation tenderness, and multiple pain conditions: a case-control study. J Pain. 2012 Oct;13(10):1016-27. doi: 10.1016/j.jpain.2012.07.011.
•   Dahlstrom L, Carlsson GE
  Temporomandibular disorders and oral health-related quality of life. A systematic review. Acta Odontol Scand. 2010 Mar;68(2):80-5. doi: 10.3109/00016350903431118.
•   Dworkin SF, Huggins KH, LeResche L, Von Korff M, Howard J, Truelove E, Sommers E
  Epidemiology of signs and symptoms in temporomandibular disorders: clinical signs in cases and controls. J Am Dent Assoc. 1990 Mar;120(3):273-81. doi: 10.14219/jada.archive.1990.0043.
•   Dworkin SF
  Temporomandibular disorder (TMD) pain-related disability found related to depression, nonspecific physical symptoms, and pain duration at 3 international sites. J Evid Based Dent Pract. 2011 Sep;11(3):143-4. doi: 10.1016/j.jebdp.2011.06.002. No abstract available.
•   Edvinsson L
  The CGRP Pathway in Migraine as a Viable Target for Therapies. Headache. 2018 May;58 Suppl 1:33-47. doi: 10.1111/head.13305.
•   Fillingim RB, Slade GD, Greenspan JD, Dubner R, Maixner W, Bair E, Ohrbach R
  Long-term changes in biopsychosocial characteristics related to temporomandibular disorder: findings from the OPPERA study. Pain. 2018 Nov;159(11):2403-2413. doi: 10.1097/j.pain.0000000000001348.
•   Goncalves DA, Bigal ME, Jales LC, Camparis CM, Speciali JG
  Headache and symptoms of temporomandibular disorder: an epidemiological study. Headache. 2010 Feb;50(2):231-41. doi: 10.1111/j.1526-4610.2009.01511.x. Epub 2009 Sep 14.
•   Goncalves DA, Camparis CM, Speciali JG, Franco AL, Castanharo SM, Bigal ME
  Temporomandibular disorders are differentially associated with headache diagnoses: a controlled study. Clin J Pain. 2011 Sep;27(7):611-5. doi: 10.1097/AJP.0b013e31820e12f5.
•   Goncalves DA, Speciali JG, Jales LC, Camparis CM, Bigal ME
  Temporomandibular symptoms, migraine, and chronic daily headaches in the population. Neurology. 2009 Aug 25;73(8):645-6. doi: 10.1212/WNL.0b013e3181b389c2. No abstract available.
•   Greene CS; American Association for Dental Research
  Diagnosis and treatment of temporomandibular disorders: emergence of a new care guidelines statement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Aug;110(2):137-9. doi: 10.1016/j.tripleo.2010.04.032. No abstract available.
•   Hurst H, Bolton J
  Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004 Jan;27(1):26-35. doi: 10.1016/j.jmpt.2003.11.003.
•   Johansson A, Unell L, Carlsson GE, Soderfeldt B, Halling A
  Gender difference in symptoms related to temporomandibular disorders in a population of 50-year-old subjects. J Orofac Pain. 2003 Winter;17(1):29-35.
•   Kamisaka M, Yatani H, Kuboki T, Matsuka Y, Minakuchi H
  Four-year longitudinal course of TMD symptoms in an adult population and the estimation of risk factors in relation to symptoms. J Orofac Pain. 2000 Summer;14(3):224-32.
•   Kimos P, Biggs C, Mah J, Heo G, Rashiq S, Thie NM, Major PW
  Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial. Pain. 2007 Jan;127(1-2):151-60. doi: 10.1016/j.pain.2006.08.028. Epub 2006 Oct 9.
•   King CT, Gegg CV, Hu SN, Sen Lu H, Chan BM, Berry KA, Brankow DW, Boone TJ, Kezunovic N, Kelley MR, Shi L, Xu C
  Discovery of the Migraine Prevention Therapeutic Aimovig (Erenumab), the First FDA-Approved Antibody against a G-Protein-Coupled Receptor. ACS Pharmacol Transl Sci. 2019 Sep 3;2(6):485-490. doi: 10.1021/acsptsci.9b00061. eCollection 2019 Dec 13.
•   Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, Silvestrini M
  Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety. Drugs. 2019 Mar;79(4):417-431. doi: 10.1007/s40265-019-01069-1.
•   Manfredini D, Favero L, Gregorini G, Cocilovo F, Guarda-Nardini L
  Natural course of temporomandibular disorders with low pain-related impairment: a 2-to-3-year follow-up study. J Oral Rehabil. 2013 Jun;40(6):436-42. doi: 10.1111/joor.12047. Epub 2013 Mar 22.
•   Markiewicz MR, Ohrbach R, McCall WD Jr
  Oral behaviors checklist: reliability of performance in targeted waking-state behaviors. J Orofac Pain. 2006 Fall;20(4):306-16.
•   Mersfelder TL, Nichols WH
  Gabapentin: Abuse, Dependence, and Withdrawal. Ann Pharmacother. 2016 Mar;50(3):229-33. doi: 10.1177/1060028015620800. Epub 2015 Dec 31.
•   Ohrbach R, Dworkin SF
  Five-year outcomes in TMD: relationship of changes in pain to changes in physical and psychological variables. Pain. 1998 Feb;74(2-3):315-26. doi: 10.1016/s0304-3959(97)00194-2.
•   Ohrbach R, Gale EN
  Pressure pain thresholds, clinical assessment, and differential diagnosis: reliability and validity in patients with myogenic pain. Pain. 1989 Nov;39(2):157-169. doi: 10.1016/0304-3959(89)90003-1.
•   Ohrbach R, Granger C, List T, Dworkin S
  Preliminary development and validation of the Jaw Functional Limitation Scale. Community Dent Oral Epidemiol. 2008 Jun;36(3):228-36. doi: 10.1111/j.1600-0528.2007.00397.x.
•   Ohrbach R, Larsson P, List T
  The jaw functional limitation scale: development, reliability, and validity of 8-item and 20-item versions. J Orofac Pain. 2008 Summer;22(3):219-30.
•   Ohrbach R
  AADR TMD statement is timely and necessary. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Feb;111(2):133-4; author reply 136-7. doi: 10.1016/j.tripleo.2010.10.036. No abstract available.
•   Ohrbach R
  Assessment and further development of RDC/TMD Axis II biobehavioural instruments: a research programme progress report. J Oral Rehabil. 2010 Oct;37(10):784-98. doi: 10.1111/j.1365-2842.2010.02144.x. Epub 2010 Aug 4.
•   Perrot S, Lanteri-Minet M
  Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice. Eur J Pain. 2019 Jul;23(6):1117-1128. doi: 10.1002/ejp.1378. Epub 2019 Mar 18.
•   Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J
  Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018 Nov 24;392(10161):2280-2287. doi: 10.1016/S0140-6736(18)32534-0. Epub 2018 Oct 22.
•   Romero-Reyes M, Pardi V, Akerman S
  A potent and selective calcitonin gene-related peptide (CGRP) receptor antagonist, MK-8825, inhibits responses to nociceptive trigeminal activation: Role of CGRP in orofacial pain. Exp Neurol. 2015 Sep;271:95-103. doi: 10.1016/j.expneurol.2015.05.005. Epub 2015 May 14.
•   Romero-Reyes M, Uyanik JM
  Orofacial pain management: current perspectives. J Pain Res. 2014 Feb 21;7:99-115. doi: 10.2147/JPR.S37593. eCollection 2014.
•   Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, List T, Svensson P, Gonzalez Y, Lobbezoo F, Michelotti A, Brooks SL, Ceusters W, Drangsholt M, Ettlin D, Gaul C, Goldberg LJ, Haythornthwaite JA, Hollender L, Jensen R, John MT, De Laat A, de Leeuw R, Maixner W, van der Meulen M, Murray GM, Nixdorf DR, Palla S, Petersson A, Pionchon P, Smith B, Visscher CM, Zakrzewska J, Dworkin SF; International RDC/TMD Consortium Network, International association for Dental Research; Orofacial Pain Special Interest Group, International Association for the Study of Pain
  Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Groupdagger. J Oral Facial Pain Headache. 2014 Winter;28(1):6-27. doi: 10.11607/jop.1151.
•   Slade GD, Fillingim RB, Sanders AE, Bair E, Greenspan JD, Ohrbach R, Dubner R, Diatchenko L, Smith SB, Knott C, Maixner W
  Summary of findings from the OPPERA prospective cohort study of incidence of first-onset temporomandibular disorder: implications and future directions. J Pain. 2013 Dec;14(12 Suppl):T116-24. doi: 10.1016/j.jpain.2013.09.010.
•   Tchivileva IE, Hadgraft H, Lim PF, Di Giosia M, Ribeiro-Dasilva M, Campbell JH, Willis J, James R, Herman-Giddens M, Fillingim RB, Ohrbach R, Arbes SJ Jr, Slade GD
  Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial. Pain. 2020 Aug;161(8):1755-1767. doi: 10.1097/j.pain.0000000000001882.
•   Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R
  Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017 Jun;16(6):425-434. doi: 10.1016/S1474-4422(17)30083-2. Epub 2017 Apr 28.
•   Von Korff M, Ormel J, Keefe FJ, Dworkin SF
  Grading the severity of chronic pain. Pain. 1992 Aug;50(2):133-149. doi: 10.1016/0304-3959(92)90154-4.
•   Zigmond AS, Snaith RP
  The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x.

Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)

Details for clinical trial NCT05162027